Cumberland Pharmaceuticals (NASDAQ:CPIX) Receives New Coverage from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Rating) in a report released on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

NASDAQ CPIX opened at $1.74 on Wednesday. The company has a current ratio of 1.70, a quick ratio of 1.31 and a debt-to-equity ratio of 0.45. The business’s 50 day moving average is $1.86 and its two-hundred day moving average is $2.20. Cumberland Pharmaceuticals has a 12-month low of $1.55 and a 12-month high of $2.91. The stock has a market capitalization of $25.14 million, a price-to-earnings ratio of -6.21 and a beta of 0.34.

Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Rating) last announced its quarterly earnings results on Tuesday, March 7th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter. The firm had revenue of $9.12 million for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 4.76% and a negative net margin of 9.97%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in shares of Cumberland Pharmaceuticals by 6.3% during the 1st quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock worth $1,818,000 after acquiring an additional 38,100 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Cumberland Pharmaceuticals by 27.8% during the 1st quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock worth $529,000 after acquiring an additional 40,949 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Cumberland Pharmaceuticals during the 4th quarter worth approximately $46,000. Finally, True Capital Management purchased a new stake in shares of Cumberland Pharmaceuticals during the 4th quarter worth approximately $27,000. Hedge funds and other institutional investors own 16.69% of the company’s stock.

About Cumberland Pharmaceuticals

(Get Rating)

Cumberland Pharmaceuticals, Inc is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex.